Baxter International Reports Q1 2026 Results: Key Details and Shareholder Insights

Date: April 30, 2026
Company: Baxter International Inc. (NYSE: BAX)

Summary of Q1 2026 Performance

• Sales from continuing operations: \$2.7 billion, up 3% on a reported basis, but down 1% on an organic basis.
• GAAP diluted EPS (loss): (\$0.03) from continuing operations.
• Adjusted diluted EPS (non-GAAP): \$0.36, down 35% year-over-year.
• Full-year 2026 outlook: Reiterated; expects reported sales growth flat to 1%, organic sales growth approximately flat, and adjusted diluted EPS of \$1.85 to \$2.05.

Management Commentary and Strategy

President and CEO Andrew Hider stated that results were in line with expectations. Management is focused on stabilizing the business, embedding a culture of continuous improvement, and strengthening execution. The leadership acknowledges that more work remains, but is committed to delivering better and more consistent results for shareholders and the over 350 million patients Baxter serves each year.

Key Financial and Segment Highlights

• U.S. sales from continuing operations: \$1.44 billion, down 4% both reported and organic.
• International sales: \$1.27 billion, up 12% reported and 3% organic.
• Net loss from continuing operations: (\$17 million), or (\$0.03) per diluted share (GAAP).
• Adjusted net income from continuing operations: \$0.36 per diluted share, a 35% decrease mainly due to an unfavorable year-over-year comparison (prior year benefited from a one-time timing shift in expense recognition).
• Segment details:
  • Medical Products & Therapies: \$1.3 billion, up 2% reported, down 2% organic. Weaker infusion pump sales due to shipment/installation hold on Novum IQ LVP and tough comparison post-Hurricane Helene, offset by strong Advanced Surgery demand.
  • Healthcare Systems & Technologies: \$705 million, flat reported, down 2% organic. Lower Front Line Care sales due to timing and planned portfolio exits; Care & Connectivity Solutions were flat.
  • Pharmaceuticals: \$621 million, up 7% reported, up 1% organic. Continued Drug Compounding strength, partly offset by lower Injectables & Anesthesia sales.

Recent Strategic Highlights

• Launched the IV Verify Line Labeling System, an automated solution to improve medication safety.
• Showcased innovation at the AORN Global Surgical Conference, including the AAT XR spine surgical table and Dynamo Series smart stretcher.
• Expanded the Baxter Growth and Performance System (GPS) as the enterprise operating system, launching 230+ improvement initiatives in Q1, with more planned for 2026.
• Partnered with the Baxter Foundation and Pet Partners to expand therapy animal programs in U.S. healthcare settings.

Key Risks and Forward-Looking Statements

Several risks could materially impact future performance and should be closely watched by shareholders:

• Execution risks: The company is undergoing strategic changes (notably, the divestiture of the Kidney Care business in January 2025 and the Hill-Rom acquisition) and may not achieve expected benefits.
• Cost pressures: Higher tariffs, manufacturing costs, and lower absorption affected results this quarter and could persist.
• Supply chain and competitive risks: Disruptions, inflation, and continued pricing pressure could affect profitability.
• Product quality and regulatory risks: Issues remain with certain infusion pumps (e.g., Novum IQ LVP), and the company faces ongoing legal, regulatory, and cybersecurity challenges.
• Dividend policy: Baxter recently reduced its quarterly dividend to \$0.01 per share, with no guarantee of increases or continued payments.
• Share price volatility: The company’s stock has experienced significant price swings and may continue to do so.

Detailed Financial Reconciliation

• GAAP vs. Adjusted Results: Adjusted results exclude special items such as intangible asset amortization, business optimization, separation costs, product-related reserves, Hurricane Helene costs, and tax matters. These non-GAAP measures provide a clearer view of underlying performance but are not a substitute for GAAP results.
• Free Cash Flow: \$76 million in Q1 2026, a significant turnaround from a negative (\$221) million in Q1 2025. Free cash flow is defined as operating cash flow less capital expenditures.

Upcoming Investor Events

• BofA Securities 2026 Health Care Conference: May 13, 2026, 1:20 p.m. CDT
• Goldman Sachs 47th Annual Healthcare Conference: June 9, 2026, 10:20 a.m. CDT

Potential Price Sensitive/Shareholder-Relevant Issues

• Guidance reaffirmed: Despite ongoing challenges, Baxter reaffirmed its full-year 2026 outlook. Meeting or missing these targets will be a key share price driver.
• Dividend cut: The recent reduction in quarterly dividend may impact investor sentiment, especially for income-focused shareholders.
• Continued business transformation and cost initiatives: Over 230 new initiatives launched in Q1 signal ongoing efforts to reshape the business. Success or failure of these could materially impact future results and valuation.
• Product challenges: Delays or issues with key products (e.g., Novum IQ pumps) could affect sales and reputation.
• Legal, regulatory, and operational risks: Numerous ongoing uncertainties, including those related to global economic conditions, regulatory changes, and cybersecurity, could impact the company’s financial performance.

Conclusion

Baxter’s Q1 2026 results show progress in stabilizing the business post-Kidney Care divestiture, but also highlight significant ongoing challenges and risks. The company’s ability to execute on its strategic priorities, manage costs, and deliver on its reaffirmed guidance will be critical for shareholders. Investors should pay close attention to cost trends, product launches, regulatory developments, and upcoming investor events for further updates that may impact the share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

View BAXTER INTERNATIONAL INC Historical chart here